ClinicalTrials.gg
RecruitingNCT06828185PRESERVEUpdated Nov 10, 2026

Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal Orchiectomy

An interventional study of Radical inguinal orchiectomy and Radical external oblique fascia sparing orchiectomy in Testicular Cancer, sponsored by Loma Linda University. Recruiting at 2 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Loma Linda University · Not applicable, Interventional, and Other

How we know

Updated Nov 10, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 167 studies in Testicular Neoplasms with a site in United States — 21 open to participants now, 26 under way, 1 of them phase 3. Testicular Neoplasms · United States.

Planned enrollment
30th of 111
80 · median 36
Started
2026
with 5 others
No phase
25 of 167
6 open now
Primary completion
2028-09
later than 19 of 25 live
Registered
157th of 167
by date

Among the 167 studies in Testicular Neoplasms with a site in United States, this one is the 30th largest by planned enrollment of the 111 interventional ones that give a count, is one of 6 that started in 2026, is one of 25 with no phase, reaches primary completion later than 19 of the 25 other live ones, and was the 157th registered.

Testicular Neoplasms

295 studies on the registry are indexed under Testicular Neoplasms; 51 are open to participants now.

Browse Testicular Neoplasms studies →

Open to participants now

21 of the 167 studies in Testicular Neoplasms with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Testicular Neoplasms studies recruiting now, 26 (60%) set no upper age limit and 11 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Testicular Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the difference in patient-reported postoperative outcomes between two standard-of-care surgical techniques for radical orchiectomy (inguinal orchiectomy versus external oblique fascia sparing orchiectomy) for treatment of patients with suspected testicular malignancy. The main questions it aims to answer are:

  1. Does sparing the external oblique fascia during orchiectomy reduce pain after surgery?
  2. Is there a difference in narcotic consumption after surgery?
  3. Is there a difference in neuropathic pain after surgery?
  4. Is there a difference in complications after surgery?
Read the detailed description

Radical inguinal orchiectomy is the standard of care surgical approach for removing a testicle when clinically there is concern for testicular cancer. The procedure is generally minor and performed in the outpatient setting. Recent data demonstrates a trend towards high opioid prescription following this procedure in an attempt to minimize postoperative pain, which is associated with persistent new opioid use in the future. Numerous efforts have been put in place to minimize postoperative pain following scrotal procedures, with success noted when opioid sparing pathways have been adopted. However, there has been sparse data on modifications within surgical technique that could improve patient pain following this procedure.

There have been various descriptions of technique to performing a radical orchiectomy which involves removal of the diseased testicle and spermatic cord. Classically, performing a radical inguinal orchiectomy involves incision of the external oblique fascia to expose and ligate the spermatic cord. During this step, the ilioinguinal nerve is exposed and can be injured by either traction injury or inadvertent transection. Modifications to this technique have been described which involve sparing of the external oblique fascia. Both approaches are performed via a similar incision and both the testicle and spermatic cord are removed. In fascia sparing modification, the spermatic cord is controlled, dissected, and subsequently ligated at the level of the superficial inguinal ring without incising the external oblique fascia. Proponents of this approach suggest the potential for less convalescence and faster recovery due to less tissue manipulation and avoidance of disturbances to the ilioinguinal nerve. Despite this potential benefit, there is no evidence to demonstrate superiority of either approach as it relates to patient recovery.

Therefore, we propose a randomized single-blinded clinical trial investigating postoperative pain outcomes of inguinal radical orchiectomy compared to external oblique fascia sparing radical orchiectomy.

03

Conditions studied

  • Testicular Cancer

Keywords

  • orchiectomy
  • postoperative pain
  • testis cancer
  • germ cell tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants undergoing radical orchiectomy for suspected testicular
  • Testicular malignancy can be germ cell tumor or non germ cell tumors, including paratesticular tumors as long as a radical orchiectomy is planned
  • Participants over 18 years of age who can provide
  • Participants not currently using opiates for another reason
  • Regional and patients are allowed, as long as participant does not require opiates for pain related to metastatic disease
  • No for participant to receive standardized medication pathway in the peri-operative period.

Exclusion criteria

Exclusion Criteria:

  • Clinical T4 disease
  • History of illicit substance abuse (including prior opioid abuse) except for marijuana
  • Participants who underwent chemotherapy or radiotherapy prior to orchiectomy
  • Opioid use within 1 month of study enrollment
  • Participants with large testis masses requiring skin incision larger than 8 cm in size.
  • Participants with large testis masses requiring orchiectomy through an incision other than the standard transverse inguinal incision (i.e. hockey stick incision, vertical incision)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Radical inguinal orchiectomy

    Procedure: Radical inguinal orchiectomy

  • Active comparator
    Radical external oblique fascia sparing orchiectomy

    Procedure: Radical external oblique fascia sparing orchiectomy

Interventions

  • ProcedureRadical inguinal orchiectomy

    External oblique fascia will be incised during orchiectomy

  • ProcedureRadical external oblique fascia sparing orchiectomy

    External oblique fascia will be spared during orchiectomy

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Level

    Post-operative pain levels will be measured by the Short Form Inguinal Pain Score (sf-IPQ) The score range is between 0 and 12, with zero points indicating no pain and 12 points indicating the most intense pain. Scores for subjects undergoing inguinal orchiectomy will be compared to subjects undergoing external oblique fascia sparing radical orchiectomy.

    Time frame: Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7

Secondary outcomes

  1. Opioid consumption

    Subjects will self-report the total number of Oxycodone 5 mg tablets consumed for breakthrough pain during the first post-op week. There is no pre-defined range for this self-report but the higher the number of tablets consumed may be an indication of great pain intensity.

    Time frame: Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7

  2. Neuropathic Pain Level

    Post-Operative Neuropathic pain levels will be measured by the modified Barrow Neurological Institute hypesthesia scale. A total score ranging between 1 and 4, with 1 representing minimal neuropathic pain and 4 representing intense neuropathic pain.

    Time frame: Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7)

07

Study locations

2 of 2 sites recruiting
  • Loma Linda University
    Loma Linda, California 92354, United States
    Recruiting
    • Muhannad Alsyouf, MD · ContactMalsyouf@llu.edu · 9095584000
    • Muhannad Alsyouf, MD · Principal investigator
  • University of Southern California
    Los Angeles, California 90089, United States
    Recruiting
    • Siamak Daneshmand, MD · Contactdaneshma@med.usc.edu · 3238653589
    • Siamak Daneshmand · Principal investigator
    • Hooman Djaladat · Sub investigator
    • Anne Schuckman · Sub investigator
08

References and documents

Publications

  • Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R. Sources of prescription opioids among diagnosed opioid abusers. Curr Med Res Opin. 2015 Apr;31(4):779-84. doi: 10.1185/03007995.2015.1016607. Epub 2015 Feb 24. PubMed 25661018 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2028, 21 months later.

Of 31 interventional studies with no phase under Testicular Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 72. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 14, 2025
StartEst.
Dec 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • University of Southern California · Los Angeles, United States
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    1 site added
    Show site
    • University of Southern California · Los Angeles, United States
    + 3 other changes: verification date, responsible party and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06828185
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
Dec 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Muhannad Alsyouf, MD
Contact
Malsyouf@llu.edu
9095584000 ext. 44196
Brian Hu, MD
Contact
Bhu@llu.edu
9095584000 ext. 44196

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion